Key Highlights
- Net loss was USD 81.7 million, or USD 0.37 per share, against USD 74.1 million, or USD 0.43.
- The FDA granted full approval for lirafugratinib, licensed to Elevar, for FGFR2-altered cholangiocarcinoma during the quarter.
- Research and development expenses were USD 77.1 million against USD 68.3 million, with no license Revenue recorded in either quarter.
- Cash, cash equivalents and investments were USD 848.6 million, which management said funds operations into 2029.
Relay Therapeutics (NASDAQ:RLAY) saw a regulatory milestone in the third quarter: in September 2026 the FDA granted full approval for LYRFIGTU (lirafugratinib) in cholangiocarcinoma with FGFR2 fusion or other rearrangement. The drug is licensed to Elevar. Relay reported a net loss of USD 0.37 per share against an estimate of USD -0.40, and no revenue against a revenue estimate of USD 1.62 million.
What the Approval Means for Relay's Agreements
Under the Elevar agreement, Relay had received USD 18.7 million as of September 30, made up of USD 5.0 million at signing, USD 3.7 million for transfer of materials and USD 10.0 million in milestone payments. It remains eligible for up to USD 485.0 million in regulatory and commercial milestone payments plus tiered royalties.
In connection with the approval, Relay owes USD 4.8 million to D. E. Shaw Research under a separate collaboration agreement, payable after September 30 and capitalized as an intangible asset.
The Quarter's Reported Figures
No license or other revenue was recognized in the third quarter of either year. For the nine months, revenue from the Elevar agreement was USD 3.35 million against USD 8.36 million.
Research and development expenses were USD 77.1 million against USD 68.3 million, and general and administrative expenses were USD 13.1 million against USD 12.1 million. Total operating expenses were USD 90.2 million against USD 80.4 million. Net loss was USD 81.7 million against USD 74.1 million. For the nine months, the net loss was USD 238.7 million, or USD 1.19 per share, against USD 221.6 million, or USD 1.30.
Zovegalisib and the Wider Pipeline
The lead candidate is zovegalisib, which the company describes as an allosteric, pan-mutant and isoform-selective PI3K Alpha inhibitor. The global Phase 3 ReDiscover-2 trial began in the second quarter of 2025 and tests zovegalisib plus fulvestrant against capivasertib plus fulvestrant in PI3K alpha-mutated, HR+/HER2- advanced breast cancer. In February 2026, the FDA granted Breakthrough Therapy Designation to the fulvestrant combination.
Interim data were announced in March 2026 for the recommended Phase 3 dose and in April 2026 for a triplet with atirmociclib, the company's go-forward triplet partner. In vascular anomalies, the Phase 1/2 ReInspire trial continues to enroll, with initial data announced in May 2026.
Balance Sheet and Funding
Cash, cash equivalents and investments were USD 848.6 million at September 30. Financing in 2026 included a May public offering of 26,354,167 shares at USD 12.00 per share, with net proceeds of USD 296.8 million. In August, the company amended its at-the-market sales agreement to raise the program size from USD 250.0 million to USD 463.0 million; through September 30 it had sold 16,006,569 shares under that agreement for net proceeds of USD 159.2 million. Management said additional capital is needed to continue developing the pipeline.
Numbers in Context
A quarterly net loss of USD 81.7 million sits alongside cash and investments of USD 848.6 million, USD 77.1 million of Research and Development spending and USD 18.7 million received to date under the Elevar agreement.
Management said the existing cash position funds operating expenses and Capital Expenditure into 2029, while noting that the estimate rests on assumptions that could prove wrong. The items it named going forward are continued enrollment in ReDiscover-2 and ReInspire, further work on the zovegalisib triplet combination with atirmociclib, payment of the USD 4.8 million owed to D. E. Shaw Research after September 30, and the potential for up to USD 485.0 million in Elevar milestones.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...